Grzegorz Dobrzanski

Grzegorz Dobrzanski


Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 February 2022 in Biomolecules
Verified
Journal Article
Open access
PDF file
MLMonika Liguz-Lecznar
Monika Liguz-Lecznar
GDGrzegorz Dobrzanski
Grzegorz Dobrzanski
MKMałgorzata Kossut
Małgorzata Kossut
Despite the obvious differences in the pathophysiology of distinct neuropsychiatric diseases or neurodegenerative disorders, some of them share some general but pivotal mechanisms, one of which is the disruption of excitation/inhibition balance. Such an imbalance can be generated by changes in the inhibitory system, very often mediated by somatostatin-containing interneurons (SOM-INs). In physiology, this group of inhibitory interneurons, as well as somatostatin itself, profoundly shapes the brain activity, thus influencing the behavior and plasticity; however, the changes in the number, density and activity of SOM-INs or levels of somatostatin are found throughout many neuropsychiatric and neurological conditions, both in patients and animal models. Here, we (1) briefly describe the brain somatostatinergic system, characterizing the neuropeptide somatostatin itself, its receptors and functions, as well the physiology and circuitry of SOM-INs; and (2) summarize the effects of the activity of somatostatin and SOM-INs in both physiological brain processes and pathological brain conditions, focusing primarily on learning-induced plasticity and encompassing selected neuropsychological and neurodegenerative disorders, respectively. The presented data indicate the somatostatinergic-system-mediated inhibition as a substantial factor in the mechanisms of neuroplasticity, often disrupted in a plethora of brain pathologies.

23 December 2019 in Brain Structure and Function
Verified
Journal Article
Open access
PDF file
AŁAgnieszka Łukomska
Agnieszka Łukomska
GDGrzegorz Dobrzanski
Grzegorz Dobrzanski
MLMonika Liguz-Lecznar
Monika Liguz-Lecznar
MKMałgorzata Kossut
Małgorzata Kossut
Inhibitory interneurons in the cerebral cortex contain specific proteins or peptides characteristic for a certain interneuron subtype. In mice, three biochemical markers constitute non-overlapping interneuron populations, which account for 80–90% of all inhibitory cells. These interneurons express parvalbumin (PV), somatostatin (SST), or vasoactive intestinal peptide (VIP). SST is not only a marker of a specific interneuron subtype, but also an important neuropeptide that participates in numerous biochemical and signalling pathways in the brain via somatostatin receptors (SSTR1-5). In the nervous system, SST acts as a neuromodulator and neurotransmitter affecting, among others, memory, learning, and mood. In the sensory cortex, the co-localisation of GABA and SST is found in approximately 30% of interneurons. Considering the importance of interactions between inhibitory interneurons in cortical plasticity and the possible GABA and SST co-release, it seems important to investigate the localisation of different SSTRs on cortical interneurons. Here, we examined the distribution of SSTR1-5 on barrel cortex interneurons containing PV, SST, or VIP. Immunofluorescent staining using specific antibodies was performed on brain sections from transgenic mice that expressed red fluorescence in one specific interneuron subtype (PV-Ai14, SST-Ai14, and VIP-Ai14 mice). SSTRs expression on PV, SST, and VIP interneurons varied among the cortical layers and we found two patterns of SSTRs distribution in L4 of barrel cortex. We also demonstrated that, in contrast to other interneurons, PV cells did not express SSTR2, but expressed other SSTRs. SST interneurons, which were not found to make chemical synapses among themselves, expressed all five SSTR subtypes.

1 April 2017 in Pharmacological Reports
Verified
Journal Article
Closed access
GDGrzegorz Dobrzanski
Grzegorz Dobrzanski
MKMałgorzata Kossut
Małgorzata Kossut

21 June 2017 in Addiction Biology
Verified
Journal Article
Closed access
PDF file
WSWojciech Barnaba Solecki
Wojciech Barnaba Solecki
KSKlaudia Szklarczyk
Klaudia Szklarczyk
KPKamil Pradel
Kamil Pradel
KKKrystyna Kwiatkowska
Krystyna Kwiatkowska
GDGrzegorz Dobrzanski
Grzegorz Dobrzanski
RPRyszard Przewłocki
Ryszard Przewłocki

1 August 2017 in European Neuropsychopharmacology
Verified
Journal Article
Closed access
WSWojciech B. Solecki
Wojciech B. Solecki
KSKlaudia Szklarczyk
Klaudia Szklarczyk
AKAdam Klasa
Adam Klasa
KPKamil Pradel
Kamil Pradel
GDGrzegorz Dobrzanski
Grzegorz Dobrzanski
RPRyszard Przewłocki
Ryszard Przewłocki

29 December 2018 in Postępy Biochemii
Verified
Journal Article
Open access
PDF file
MKMałgorzata Kossut
Małgorzata Kossut
AŁAgnieszka Łukomska
Agnieszka Łukomska
GDGrzegorz Dobrzanski
Grzegorz Dobrzanski
MLMonika Liguz-Lecznar
Monika Liguz-Lecznar
Somatostatin is a peptide that participates in numerous biochemical and signaling pathways. It functions via receptors (SSTRs1-5), which belong to the family of receptors coupled with protein G. All somatostatin receptors are characterized by a certain degree of homology in molecular structure. The cell effects of their agonists in peripheral tissues rely mainly on the inhibition of the hormones release. Somatostatin is also an important neuromodulator and neurotransmitter. SSTRs may affect other receptors, forming structural and functional homodimers and heterodimers. SSTRs play also role in the regulation of physiological processes, such as itching and pain, reproductive functions, regulation of feeding or mood. Besides physiological functions, SSTRs contribute also to the pathogenesis of glial tumors, neurodegenerative diseases, or post hemorrhagic stroke changes. Recent years of research have provided new data regarding the role of somatostatin receptor signaling pathways in the brain and the knowledge in this field is developing rapidly.